| 1 |
李慧婷，莫冉冉，宋 鹏，等. 非小细胞肺癌免疫检查点抑制剂治疗进展[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(3): 382-386.
|
| 2 |
陈宏达，郑荣寿，王 乐，等. 2019年中国肿瘤流行病学研究进展[J]. 中华疾病控制杂志，2020, 24(4): 373-379.
|
| 3 |
邓小茜，戈 伟. SBRT与IMRT治疗早期非小细胞肺癌的疗效与生存情况分析[J]. 武汉大学学报(医学版), 2020, 41(5): 754-757.
|
| 4 |
Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24): 2288-2301.
|
| 5 |
韩文杰，刘 军，孙永臣. 红参发酵产物联合长春瑞滨及顺铂化疗方案治疗晚期非小细胞肺癌患者的疗效[J]. 癌症进展，2020, 18(7): 694-698.
|
| 6 |
Proto C, Ferrara R, Signorelli D, et al. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out[J]. Cancer Treat Rev, 2019, 75(3): 39-51.
|
| 7 |
Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial [J]. Lancet Oncol, 2019, 20(5): 625-635.
|
| 8 |
黄 彬. 贝伐单抗和顺铂联合治疗非小细胞肺癌恶性胸腔积液的疗效评价[J]. 国际呼吸杂志，2016, 36(11): 814-817.
|
| 9 |
Manzo A, Montanino A, Carillio G, et al. Angiogenesis Inhibitors in NSCLC[J]. Int J Mol Sci, 2017, 18(10): 114-116.
|
| 10 |
支修益，石远凯，于金明. 中国原发性肺癌诊疗规范(2015年版)[J]. 中华肿瘤杂志，2015, 37(1): 67-78.
|
| 11 |
Reck M, Mok T, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. Lancet Respir Med, 2019, 7(5): 387-401.
|
| 12 |
Assoun S, Brosseau S, Steinmetz C, et al. Bevacizumab in advanced lung cancer: state of the art[J]. Future Oncol, 2017, 13(28): 2515-2535.
|
| 13 |
Russo AE, Priolo D, Antonelli G, et al. Bevacizumab in the treatment of NSCLC: patient selection and perspectives[J]. Lung Cancer (Auckl), 2017, 8(10): 259-269.
|
| 14 |
Alshangiti A, Chandhoke G, Ellis PM. Antiangiogenic therapies in non-small-cell lung cancer[J]. Curr Oncol, 2018, 25(7): S45-S58.
|
| 15 |
Masuda C, Yanagisawa M, Yorozu K, et al. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model [J]. Int J Oncol, 2017, 51(2): 425-434.
|
| 16 |
Ramalingam SS, Dahlberg SE, Belani CP, et al. Pemetrexed, bevacizumab，or the combination as maintenance therapy for advanced nonsquamous non-small-cell lung cancer: ECOG-ACRIN 5508[J]. J Clin Oncol, 2019, 37(26): 2360-2367.
|
| 17 |
李 航，王 莹，张春江，等. 肿瘤坏死因子相关诱导凋亡配体联合长春瑞滨联合干预诱导肺癌A549细胞凋亡及其机制[J]. 中华实验外科杂志，2016, 33(1): 112-114.
|
| 18 |
宋小珍，贾亚辉，张跃强. 长春瑞滨联合阿帕替尼治疗中晚期非小细胞肺癌的临床疗效及预后观察[J]. 实用癌症杂志，2020, 35(12): 1997-2000.
|
| 19 |
Herbst RS, Redman MW, Kim ES, et al. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study[J]. Lancet Oncol, 2018, 19(1): 101-114.
|
| 20 |
Dhillon S, Syed YY. Atezolizumab first-line combination therapy: a review in metastatic nonsquamous NSCLC[J]. Target Oncol, 2019, 14(6): 759-768.
|
| 21 |
薛 琴，传锋彬，唐 甦. CT引导下125I粒子植入联合贝伐单抗对非小细胞肺癌的疗效[J]. 实用癌症杂志，2020, 35(3): 418-420.
|
| 22 |
Manegold C, Dingemans AC, Gray JE, et al. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC[J]. J Thorac Oncol, 2017, 12(2): 194-207.
|
| 23 |
Reck M, Wehler T, Orlandi F, et al. Safety and patient-reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab versus bevacizumab plus chemotherapy in non-small-cell lung cancer[J]. J Clin Oncol, 2020, 38(22): 2530-2542.
|
| 24 |
Jiang T, Zhang Y, Li X, et al. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases[J]. Eur J Cancer, 2019, 121(7): 98-108.
|
| 25 |
Wakelee HA, Dahlberg SE, Keller SM, et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1610-1623.
|
| 26 |
Reinmuth N, Bryl M, Bondarenko I, et al. PF-06439535 (a bevacizumab biosimilar) compared with reference bevacizumab (Avastin((R))), both plus paclitaxel and carboplatin, as first-line treatment for advanced non-squamous non-small-cell lung cancer: a randomized, double-blind study[J]. BioDrugs, 2019, 33(5): 555-570.
|
| 27 |
Reck M, Shankar G, Lee A, et al. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations[J]. Expert Rev Respir Med, 2020, 14(2): 125-136.
|
| 28 |
Thatcher N, Goldschmidt JH, Thomas M, et al. Efficacy and Safety of the Biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): A randomized, double-blind, phase Ⅲ study[J]. Clin Cancer Res, 2019, 25(7): 2088-2095.
|
| 29 |
Gridelli C, de Castro CJ, Dingemans AC, et al. Safety and efficacy of bevacizumab plus standard-of-care treatment beyond disease progression in patients with advanced non-small cell lung cancer: The AvaALL randomized clinical trial[J]. JAMA Oncol, 2018, 4(12): e183-e186.
|
| 30 |
Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial[J]. JAMA Oncol, 2018, 4(1): e173-e175.
|